HairDX Announces Clinical Trial of Genetically Tailored Therapy for Female Baldness

Pharmacogenomics research and development innovator PharmaGenoma, Inc. and its subsidiary HairDX, LLC, has announced that it has received institutional review board (IRB) approval to begin a clinical trial of a genetically tailored therapy for female baldness (Androgenetic Alopecia).

“Our goal is to revolutionize the field of dermatology by innovating genetically tailored treatments to common skin disorders,” said Andy Goren, Chairman and Chief Strategist of PharmaGenoma, Inc and HairDX, LLC.

HairDX will soon begin recruiting post menopausal women as patients for the study. Women who qualify for the study will undergo genetic screening. If they exhibit a particular genetic variation in their Androgen Receptor gene, they will receive a drug that may potentially re-grow their hair. The trial is expected to start in the early Fall.

“To date, no systemic drug treatment is available for Female Androgenetic Alopecia. The HairDX drug trial may usher a new era in the treatment of Female Androgenetic Alopecia," said Antonella Tosti, MD, Professor of Dermatology at the University of Bologna in Italy.

“Dermatologists often prescribe women drugs for the treatment of hair loss; however, only a fraction of women respond to the therapy. If the HairDX clinical trial proves successful, dermatologists will be able to individually tailor treatment for hair loss based on a woman’s genetic makeup,” said Professor Doron Lancet, Head of the Crown Human Genome Center at the Department of Molecular Genetics, Weizmann Institute of Science.

Earlier this year, HairDX became the first company to market genetic tests that predict an individual’s risk for the male or female versions of Androgenetic Alopecia. The test is available through physicians.